Timothy Sullivan E.'s most recent trade in Apellis Pharmaceuticals Inc was a trade of 82,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 9, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2025 | 82,500 | 82,500 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 29.52 per share. | 29 Jan 2025 | 546 | 128,665 (0%) | 0% | 29.5 | 16,120 | Common Stock |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.43 per share. | 22 Jan 2025 | 3,088 | 129,211 (0%) | 0% | 30.4 | 93,954 | Common Stock |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 45,929 | 132,299 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 29.96 per share. | 17 Jan 2025 | 1,730 | 86,370 (0%) | 0% | 30.0 | 51,828 | Common Stock |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 28.70 per share. | 13 Jan 2025 | 2,170 | 88,100 (0%) | 0% | 28.7 | 62,284 | Common Stock |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 10,054 | 84,946 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.85 per share. | 31 Dec 2024 | 10,054 | 90,270 (0%) | 0% | 13.9 | 139,248 | Common Stock |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 1,042 | 23,958 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.95 per share. | 31 Dec 2024 | 1,042 | 80,216 (0%) | 0% | 15.0 | 15,578 | Common Stock |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Apr 2024 | 14,164 | 79,174 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Apr 2024 | 14,164 | 70,396 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 58.66 per share. | 01 Apr 2024 | 4,000 | 93,338 (0%) | 0% | 58.7 | 234,640 | Common Stock |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 4,000 | 257,903 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.03 per share. | 01 Apr 2024 | 4,000 | 97,338 (0%) | 0% | 10.0 | 40,120 | Common Stock |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 6,000 | 261,903 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.03 per share. | 01 Mar 2024 | 6,000 | 99,338 (0%) | 0% | 10.0 | 60,180 | Common Stock |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 62.86 per share. | 01 Mar 2024 | 4,000 | 95,338 (0%) | 0% | 62.9 | 251,440 | Common Stock |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 63.95 per share. | 01 Mar 2024 | 2,000 | 93,338 (0%) | 0% | 64.0 | 127,900 | Common Stock |
| Apellis Pharmaceuticals Inc | Sullivan Timothy E. | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 67.77 per share. | 12 Feb 2024 | 1,431 | 93,338 (0%) | 0% | 67.8 | 96,974 | Common Stock |
| Apellis Pharmaceuticals Inc | Timothy Sullivan E. | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 64.14 per share. | 29 Jan 2024 | 906 | 94,769 (0%) | 0% | 64.1 | 58,109 | Common Stock |
| Apellis Pharmaceuticals Inc | E. Sullivan Timothy | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 65.00 per share. | 22 Jan 2024 | 3,551 | 95,675 (0%) | 0% | 65.0 | 230,801 | Common Stock |
| Apellis Pharmaceuticals Inc | Sullivan E. Timothy | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2024 | 34,533 | 34,533 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2024 | 23,748 | 101,461 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | E. Sullivan Timothy | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 66.81 per share. | 16 Jan 2024 | 2,235 | 99,226 (0%) | 0% | 66.8 | 149,317 | Common Stock |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jul 2023 | 6,779 | 282,061 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.03 per share. | 03 Jul 2023 | 6,779 | 84,492 (0%) | 0% | 10.0 | 67,993 | Common Stock |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 90.42 per share. | 03 Jul 2023 | 3,287 | 78,013 (0%) | 0% | 90.4 | 297,199 | Common Stock |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 89.41 per share. | 03 Jul 2023 | 3,192 | 81,300 (0%) | 0% | 89.4 | 285,400 | Common Stock |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 91.10 per share. | 03 Jul 2023 | 300 | 77,713 (0%) | 0% | 91.1 | 27,329 | Common Stock |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.03 per share. | 05 Jun 2023 | 69,779 | 147,492 (0%) | 0% | 10.0 | 699,883 | Common Stock |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2023 | 69,779 | 288,840 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 87.79 per share. | 05 Jun 2023 | 30,609 | 115,283 (0%) | 0% | 87.8 | 2,687,121 | Common Stock |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 89.83 per share. | 05 Jun 2023 | 30,506 | 77,713 (0%) | 0% | 89.8 | 2,740,229 | Common Stock |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 88.36 per share. | 05 Jun 2023 | 7,064 | 108,219 (0%) | 0% | 88.4 | 624,210 | Common Stock |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 90.60 per share. | 05 Jun 2023 | 1,600 | 145,892 (0%) | 0% | 90.6 | 144,967 | Common Stock |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 03 May 2023 | 20,000 | 77,713 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 03 May 2023 | 20,000 | 56,232 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Apr 2023 | 36,232 | 36,232 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Apr 2023 | 36,232 | 97,713 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 16,572 | 16,572 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 11,683 | 134,919 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.50 per share. | 21 Feb 2023 | 974 | 133,945 (0%) | 0% | 58.5 | 56,979 | Common Stock |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.21 per share. | 10 Feb 2023 | 975 | 123,236 (0%) | 0% | 51.2 | 49,930 | Common Stock |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.77 per share. | 27 Jan 2023 | 551 | 124,211 (0%) | 0% | 52.8 | 29,076 | Common Stock |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.05 per share. | 20 Jan 2023 | 2,379 | 124,762 (0%) | 0% | 52.1 | 123,827 | Common Stock |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2022 | 43,183 | 43,183 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2022 | 27,488 | 127,141 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Other type of transaction at price $ 0.00 per share. | 25 Apr 2022 | 22,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Other type of transaction at price $ 0.00 per share. | 25 Apr 2022 | 3,750 | 99,653 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.12 per share. | 10 Feb 2022 | 875 | 103,403 (0%) | 0% | 47.1 | 41,230 | Common Stock |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.59 per share. | 28 Jan 2022 | 650 | 104,278 (0%) | 0% | 38.6 | 25,084 | Common Stock |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2022 | 43,670 | 43,670 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2022 | 30,787 | 104,928 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2021 | 39,880 | 358,619 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.03 per share. | 08 Jun 2021 | 39,880 | 74,141 (0%) | 0% | 10.0 | 399,996 | Common Stock |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.72 per share. | 10 Feb 2021 | 858 | 34,261 (0%) | 0% | 47.7 | 40,944 | Common Stock |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2021 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2021 | 22,500 | 22,500 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2021 | 7,500 | 31,369 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Timothy E. Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2021 | 3,750 | 35,119 (0%) | 0% | 0 | Common Stock |